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Translational Cancer Research, Chang Gung Memorial Hospital, Taoyuan, Taiwan

Purpose: A phase 3 randomized study (COG ANBL0032) demonstrated significantly
improved outcome by adding immunotherapy with ch14.18 antibody to isotretinoin as
post-consolidation therapy for high-risk neuroblastoma (NB). This study, ANBL0931,
was designed to collect FDA-required safety/toxicity data to support FDA registration
of ch14.18.
Experimental design: Newly diagnosed high-risk NB patients who achieved at least
a partial response to induction therapy and received myeloablative consolidation with
stem cell rescue were enrolled to receive six courses of isotretinoin with five concomitant
cycles of ch14.18 combined with GM-CSF or IL2. Ch14.18 infusion time was 10–20 h
per dose. Blood was collected for cytokine analysis and its association with toxicities
and outcome.
Results: Of 105 patients enrolled, five patients developed protocol-defined unacceptable
toxicities. The most common grade ≥ 3 non-hematologic toxicities of immunotherapy for
cycles 1–5, respectively, were neuropathic pain (41, 28, 22, 31, 24%), hypotension (10, 17,
4, 14, 8%), allergic reactions (ARs) (3, 10, 5, 7, 2%), capillary leak syndrome (1, 4, 0,
2, 0%), and fever (21, 59, 6, 32, 5%). The 3-year event-free survival and overall survival
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were 67.6 ± 4.8% and 79.1 ± 4.2%, respectively. AR during course 1 was associated
with elevated serum levels of IL-1Ra and IFNγ, while severe hypotension during this
course was associated with low IL5 and nitrate. Higher pretreatment CXCL9 level was
associated with poorer event-free survival (EFS).
Conclusion: This study has confirmed the significant, but manageable treatment-related
toxicities of this immunotherapy and identified possible cytokine biomarkers associated
with select toxicities and outcome. EFS and OS appear similar to that previously reported
on ANBL0032.
Keywords: neuroblastoma, immunotherapy, anti-GD2 chimeric antibody, cytokines, safety, cytokine biomarkers

INTRODUCTION

MATERIALS AND METHODS

Immunotherapy using anti-glycolipid disialoganglioside (GD2)
antibody combined with cytokines has become the standard
treatment in North America for patients with high-risk neuroblastoma (NB) who have achieved at least a partial remission
following intensive induction and consolidation (1). Induction
treatment consists of 5–6 cycles of multiagent chemotherapy
combined with surgery followed by the consolidation phase that
includes single or tandem autologus stem cell transplant with
subsequent radiotherapy. Several anti-GD2 antibodies have
been tested for clinical use including murine 3F8, chimeric 14.18
(ch14.18, dinutuximab), humanized 14.18 (hu14.18K322A),
and humanized 14.18 fused to interleukin-2 (hu14.18-IL2)
(2–5). Ch14.18 is an anti-GD2 monoclonal antibody, which is a
chimeric construct composed of the variable region heavy and
light chain genes of the murine mAb14.G2a and the human constant region genes for heavy chain IgG1 and light chain kappa
(6). The primary objective of this study was to comprehensively
define the safety profile of ch14.18 when administered with
cytokines and isotretinoin in high-risk NB patients after completing standard induction chemotherapy and autologous stem
cell transplant (ASCT) and generate data required to support
the Biological License Application (BLA) for ch14.18 with the
Food and Drug Administration (FDA).
Cytokine release often occurs during antibody-based immuno
therapeutics and is commonly associated with infusion reactions
and other toxicities. Therapeutic IL-2 not only induces immune
cell stimulation but may also induce hypotension and capillary
leak syndrome. This is believed to be mediated by nitric oxide
(NO) directly or indirectly via induction of tumor necrosis
factor alpha (TNFα) and interferon gamma (IFNγ) or other
proinflammatory cytokines such as IL-6 (7–9). Cytokine release
in response to other immunotherapies is common and believed
to be responsible for associated toxicities (10). Cytokines have
also been implicated in patient survival, with increased IL-6
levels at diagnosis associated with poor outcome in numerous
cancers including NB (10, 11). However, the relationship of
cytokine levels with outcome from immunotherapy has never
been investigated. Thus, serum cytokine profiles during ch14.18
immunotherapy may be able to predict toxicities and/or outcome
of the immunotherapy and were thus investigated as part of
this study.

Patient Population

Frontiers in Immunology | www.frontiersin.org

All NB patients categorized as high-risk at the time of diagnosis,
and met the International Neuroblastoma Response Criteria
(INRC) for complete response, very good partial response (PR),
or PR for primary site, soft tissue, bone metastases at their preASCT evaluation at study entry were eligible [(12), described
in online Appendix]. High-risk patients were International
Neuroblastoma Staging System (INSS) stage 4 greater than
18 months of age, INSS stage 4 with MYCN amplification, regardless of age, INSS stage 4 between ages of 12 and 18 months with
unfavorable histology and/or diploid tumor DNA content, INSS
stage 3 with amplified MYCN, regardless of age, INSS stage 3 and
unfavorable histology greater than 18 months of age, INSS stage
2 with MYCN amplification regardless of age. In addition, all
patients must have completed therapy including intensive induction chemotherapy followed by myeloablative consolidation with
ASCT and radiotherapy, including enrollment onto contemporary clinical trials within the Children’s Oncology Group or
New Advances in Neuroblastoma Research (regimen specifics
included in Appendix, online only). No more than 9 months from
the date of starting the first induction chemotherapy to the date
of ASCT was allowed. Patients had to be enrolled no later than
Day 100 after ASCT infusion (or day 100 from second stem cell
infusion if tandem transplant). Patients had to be enrolled after
completion of radiotherapy post-ASCT, and after completion of
tumor assessment post-radiotherapy. There was no age restriction. Patients who had received prior anti-GD2 therapy were
excluded. Other organ-specific and inclusion/exclusion criteria
are provided in the Appendix (online only).
Written informed consent was obtained from parents or legal
guardians. Patients were treated at thirty Children’s Oncology
Group institutions on a protocol approved by the institution’s
local Institutional Review Board (IRB) or National Cancer
Institute (NCI)-sponsored pediatric central institutional review
board (NCT01041638; see Appendix for the list of institutions,
online only).

Study Design

All patients received six courses of isotretinoin (ISOT). For
the first five of these courses, patients also received ch14.18
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plus cytokines, with ch14.18 and sargramostim (granulocyte
macrophage-colony stimulating factor, GM-CSF) administered
in Courses 1, 3, and 5, and ch14.18 with aldesleukin (IL-2) given
in Courses 2 and 4 (Figure 1) Ch 14.18 was administered every
28 days, as described previously (1).

Toxicities were graded according to the Common Termino
logy Criteria for Adverse Events (version 4.0). Grades 1 through
5 toxicities were captured. Unacceptable toxicities were defined
as: Grade ≥ 4 allergic reaction (AR), anaphylaxis, Grade ≥ 4 capillary leak syndrome, Grade ≥ 3 peripheral motor neuropathy

A

B

C

Figure 1 | Immunotherapy treatment schema. (A) Schedule of overall dinutuximab, GM-CSF, IL2, and 13cisRA. (B) Treatment schema for courses 1, 3, and 5 with
GM-CSF (28 days per course). (C) Treatment schema for courses 2 and 4 with IL2.
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Cytokine and Nitrate Analysis

with duration ≥ 2 weeks, and Grade ≥ 4 pain, requiring narcotics/
lidocaine and persisting ≥ 4 days after the end of ch14.18
infusion. AR was defined to include bronchospasm, stridor,
wheezing, urticarial, and anaphylaxis. Special attention was
placed on toxicities resulting from direct neuronal toxicity or
from immune/cytokine reactions extrapolated from similar data
based on ANBL0032 (NCT01418495). Required pretreatment
and on-study observations were used to monitor toxicity and
criteria for dose modifications (Appendix, online only). Tumor
response was reported using INRC.

Heparinized blood and serum samples were collected
before starting immunotherapy and just before the fourth
doses of ch14.18 infusion on courses 1 (days −1 and 6) and
4 (days 80 and 90) and shipped by overnight courier for lab
analyses. Most analytes were measured using SimplePlex assays
(ProteinSimple, San Jose, CA, USA) except the following: IL-6
by the Meso Scale Discovery (MSD, Rockville, MD, USA) IL-6
assay, IL-1 receptor antagonist (IL-1Ra) by the R&D Systems
assay (R&D Systems, Minneapolis, MN, USA), and nitrate by
the R&D Systems Parameter Total Nitric Oxide and Nitrate/
Nitrite Kit.

Drug Supply and Administration

Ch14.18 was supplied by the National Cancer Institute and
administered to hospitalized patients intravenously over a
minimum of 10 h at 25 mg/m2/day for four consecutive days
every 28 days. This dose is the equivalent of the currently
FDA approved dinutuximab dose of 17.5 mg/m2/day. Ch14.18
infusion was started at 1.25 mg/m2/h for the first 0.5 h, then,
increased to 2.5 mg/m2/h for the remainder of the dose, if
tolerated, to be administered over ≥10 h. The maximum infusion time from initiation of ch14.18 was 20 h even if the total
dose had not been administered in that timeframe. Patients
were pre-medicated with diphenhydramine or hydroxyzine,
acetaminophen and recommended to be on intravenous (IV)
narcotics as a loading dose immediately prior to ch14.18
administration followed by continuous IV infusion narcotics.
During courses 1, 3, and 5, commercially available GM-CSF
was administered either subcutaneously (strongly recommended) or IV over 2 h at 250 µg/m2/day for 14 days. Ch14.18
was started on the fourth day of GM-CSF injections, 1 h after
GM-CSF and immediately following a 10 ml/kg IV bolus of
normal saline each day. During course 2 and 4, commercially
available aldesleukin (IL-2) at 3 Million International Units/
m2/day was administered by IV continuous infusion for 96 h.
Seven days later, patients received an additional 4.5 Million
IU/m2/day of aldesleukin administered by IV continuous
infusion over 96 h along with simultaneous administration of
ch14.18. Isotretinoin at 80 mg/m2/dose (2.67 mg/kg/dose if
weight ≤ 12 kg) was administered by mouth twice daily (BID)
for 14 days, every 28 days starting on day 11 for course 1, day
10 for courses 3 and 5, and day 14 for courses 2 and 4. Patients
received only isotretinoin for course 6 (same dose as in previous courses) starting 14 days after completion of course 5.
The use of corticosteroids and other immunosuppressive medi
cations were prohibited, except for life-threatening conditions
(i.e., life-threatening AR, including anaphylaxis, bronchospasm,
and stridor) unresponsive to other measures. Other supportive
care measures are listed in the Appendix (online only).

Human Anti-Chimeric Antibody
(HACA) Studies

A validated MSD electrochemiluminescent assay was used to
measure HACA (BioAgilytix, Durham, NC, USA). Methodological
details are included in Appendix (Online only).

Statistical Analysis

In accordance with the protocol, analyses were performed as
intent-to-treat. Toxicity data were summarized using proportions with two-sided 95% Wilson (score) confidence intervals.
For selected toxicities of interest, the median, minimum, and
maximum duration were calculated. Protocol monitoring
rules for unacceptable toxicity (two-stage design) and toxic
death were applied. McNemar’s test for paired data was used to
compare the incidence of toxicities between GM-CSF (cycles
1, 3, and 5) and IL-2 (cycles 2 and 4) containing courses in
patients with at least one course of each. Event-free survival
(EFS) and overall survival (OS) curves were generated using
the methods of Kaplan and Meier, with standard errors per Peto
et al. (14, 15). For EFS, the time to event was calculated from
study enrollment until the first occurrence of relapse, progressive disease, secondary malignancy, death, or until last contact
if no event occurred. For OS, it was time from enrollment until
death, or until last contact with the patient. Cytokine levels
during courses were compared by Wilcoxon signed-rank test
comparison of paired samples: day −1 versus day 6 and day 80
versus day 90. A p-value of <0.0036 was considered statistically
significant at level 0.05 after Bonferroni correction for the 14
cytokine compared at each course. A two-sided Mann–Whitney
U-test was used to compare analyte levels in patients experiencing a vascular toxicity (hypotension or capillary leak) or AR
(anaphylaxis, urticaria, wheezing, stridor, bronchospasm, and
generally diagnosed AR) versus no AR and was considered
statistically significant at p ≤ 0.05.

Pharmacokinetic Studies

RESULTS

Plasma ch14.18 levels were quantified using an electrochemiluminescence immunoassay (BioAgilytix, Durham, NC, USA)
as previously described (13). Samples were obtained before
starting GM-CSF and after ch14.18 in Courses 1 and 5 and prior
to IL-2 and after ch14.18 and IL-2 in Course 4. A final sample
was obtained within 2 weeks after the last dose of isotretinoin in
Course 6.

Frontiers in Immunology | www.frontiersin.org

Patient Characteristics

One hundred and five patients were enrolled. One patient
withdrew consent prior to the initiation of therapy, but remains
included in these intent-to-treat analyses. Ninety-three percent of
the patients were less than 12 years old. Patient characteristics are
summarized in Table 1.
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Toxicities

Table 1 | Characteristics of patients enrolled on COG ANBL0931 (n = 105).

Five patients developed protocol-defined unacceptable toxicities and came off study: four Grade 4 AR and one sudden death
(Table 2). The pre-specified monitoring rule for too many unacceptable toxicities was not met. Sudden death occurred in one
patient who had been clinically stable while awaiting start of
course 2 of immunotherapy. The patient experienced sudden onset
of abdominal pain and subsequent cardiac arrest and unable to
be resuscitated by paramedics. No autopsy was performed. Three
more patients discontinued the study as per parents/physician
choice secondary to immunotherapy-related toxicities.
The proportion of patients experiencing clinically relevant
toxicities, all grades, across all cycles of therapy are summarized
in Table 3 (Grade 1 and 2 toxicities provided in Table S1 in
Supplementary Material). The most common Grade 3 or higher
non-hematologic toxicities of immunotherapy were neuropathic
pain and fever, followed by, hypotension, AR, and capillary leak
syndrome (Table 4). Of the 104 patients who received course 1,
103 (99%) experienced at least one Grade 3 or greater toxicity
(data not shown). Pain occurred more frequently during Course
1, then, at lower rates thereafter (Tables 3 and 4). There was
not a statistically significant difference for AR, capillary leak
syndrome and hypotension between GM-CSF vs IL-2 courses.
Although not statistically significant, capillary leak syndrome
and grades 3–4 hypotension occurred at higher rates during the
IL-2 courses. The median duration of select adverse events is
presented in Table 5. Most toxicities resolved within 3 days
with the exception of the rare ocular and hypertension toxicity
(Table 5). Dose reduction of ch14.18 was reported in 45 patients
(43.27%), i.e., these patients received less than 90% of the intended
dose at some point during courses 1–5. Of the 45 patients with
dose reductions, ARs, capillary leak, and hypotension were the
main indications. Of the 104 patients who received treatment
79 patients received ≥ 90%, 8 patients ≥ 80 to <90%, 9 patients
≥70 to <80%, 1 patient ≥ 60 to <70%, 3 patients ≥ 50 to <60%,
and 4 patients received <50% of the cumulative intended dose of
ch14.18. The use of morphine, fentanyl, meperidine, hydromorphone, and ketamine were reported in 100 patients at some point
during the study. In 20 of the 104 patients (19.2%), GM-CSF was
administered intravenously instead of subcutaneously.

Age, years
Median
Range
Sex
Male
Female
Race
White
Black
Other
Ethnicity
Hispanic
Other
Histology
Favorable
Unfavorable
Unknown
INSS stage
Stage 1a
Stage 2b
Stage 3
Stage 4
Unknown
MYCN status
Non-amplified
Amplified
Unknown
Number of ASCTs prior to study
One
Two
Disease status at study entry
Complete response
Very good partial response (PR)
PR

4.1
1.1–27.5
59 (56.2%)
46 (43.8%)
82 (78.1%)
10 (9.5%)
13 (12.4%)
9 (8.6%)
96 (91.4%)
4 (5.5%)
69 (94.5%)
32
2 (2.5%)
1 (1.2%)
15 (18.5%)
63 (77.8%)
24
40 (57.1%)
30 (42.9%)
35
88 (83.8%)
17 (16.2%)
29 (27.6%)
36 (34.3%)
40 (38.1%)

a
MYCN amplified tumor (n = 1), progression to metastatic disease meeting high-risk
criteria during follow-up (n = 1).
b
MYCN amplified tumor.

Table 2 | Toxicities defined as “Unacceptable” according to COG protocol
ANBL0931 (n = 105 patients enrolled).
Course

Number of patients with
unacceptable toxicities

Course 1 (n = 104)

2

Course 2 (n = 100)
Course 3 (n = 98)
Course 4 (n = 90)
Course 5 (n = 88)
Course 6 (n = 81)

1
1
1
0
0

Description of the
unacceptable toxicity
Grade 4 allergic reaction (AR)/
anaphylaxis (n = 1); grade 5
cardiac arrest (n = 1)
Grade 4 AR
Grade 4 AR
Grade 4 anaphylaxis
None
None

Pharmacokinetics

The mean ch14.18 concentration appeared to be similar during
the peak of the three courses studied (first, third, and fourth),
with mean concentrations of 5,965, 4,650, and 5,907 ng/ml,
respectively (Table 6). Ch14.18 was still detectable at its trough

Table 3 | Proportion of patients with Grades 1–5 toxicities attributed to ch14.18 on COG study ANBL0931.

Course 1 (n = 104)
Course 2 (n = 100)
Course 3 (n = 98)
Course 4 (n = 90)
Course 5 (n = 88)
Course 6 (n = 81)

Pain (%)

Allergic reactions (%)

Capillary leak syndrome (%)

Hypotension (%)

Fever (%)

Ocular toxicity (%)

93
78
79
77
70
26

25
28
16
21
13
0

24
39
14
33
17
0

60
64
58
69
52
14

91
92
69
87
67
19

2
3
3
1
1
0

Frontiers in Immunology | www.frontiersin.org
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Table 4 | Proportion of patients (95% confidence interval) with clinically significant Grade 3 and 4 toxicities attributed to ch14.18 on COG study ANBL0931 (courses 1,
3, and 5 contained GM-CSF and Courses 2 and 4 contained IL-2).

Course 1 (n = 104)
Course 2 (n = 100)
Course 3 (n = 98)
Course 4 (n = 90)
Course 5 (n = 88)

Pain

Allergic reactions

Capillary leak syndrome

Hypotension

Fever

41% (32.4, 51.0%)
28% (20.1, 37.5%)
22% (15.3, 31.7%)
31% (22.5, 41.3%)
24% (16.2, 33.7%)

3% (0.9, 8.1%)
10% (5.5, 17.4%)
5% (2.2, 11.4%)
7% (3.1, 13.8%)
2% (0.6, 7.9%)

1% (0.2, 5.2%)
4% (1.6, 9.8%)
0% (0.0, 3.8%)
2% (0.6, 7.7%)
0% (0.0, 4.2%)

10% (5.3, 16.8%)
17% (10.9, 25.6%)
4% (1.6, 10.0%)
14% (8.6, 23.2%)
8% (3.9, 15.5%)

21% (14.4, 30.0%)
59% (49.2, 68.1%)
6% (2.8, 12.7%)
32% (23.5, 42.4%)
5% (1.8, 11.1%)

Table 5 | Median duration (in days) of select adverse events within the subset of patients who experienced those eventsa.
Courses 1, 3, or 5
(with GM-CSF) (n = 104)
Toxicities

Courses 2 or 4
(with IL-2) (n = 100)

Anytime on treatment

N with toxicity

Median duration (days)

N with toxicity

Median duration (days)

N with toxicity

Median duration (days)

54
14
54
1
8
1
28

2.0
3.5
2.0
2.0
1.5
238.0
1.0

38
6
39
6
13
2
63

2.0
69.0
2.0
2.5
2.0
7.0
2.0

64
19
64
7
17
3
70

2.5
5.0
3.0
2.0
2.0
13.0
2.0

Neuropathic pain
Ocular toxicitiescb
Anatomical paind
Capillary leak syndrome
Allergic reaction
Hypertension
Fever

a
For a given adverse event, the longest duration of an event was selected per patient per treatment course. Only Grades 3–4 were used in calculations unless otherwise specified
(the Grade 5 cardiac arrest has been excluded from this table).
b
One ocular toxicity was ongoing and had no date of resolution. This record is omitted from calculations.
c
All grades were used for calculations.
d
See Table S1 in Supplementary Material for the description of anatomical pain.

The average cytokine levels of patients with AR were indistinguishable from the overall population, with no significant
differences in the levels of the cytokines between the “non-AR”
versus the “any AR” population of patients, except for course 1
(day 6) IL-1Ra (2,043.6 vs 2,522.3 pg/ml, p = 0.02) and IFNγ (35.9
vs 73.8 pg/ml, p = 0.02), though neither was significant at course
4 (day 90) (Figure 2B; Table S2 in Supplementary Material).
Similarly, when levels for each of the cytokines were compared
for patients with no or Grade 1 AR versus patients with Grade ≥ 2
AR, no associations were identified (data not shown). At each
time point, we then investigated the 14 individual patients with
the highest level of each of the 14 cytokines. At day 6, the patients
with “extreme” cytokine levels were as likely to be associated with
the non-AR group as with the AR group (7 of 14 cytokines in
each group). At day 90, only 3 of the patients with the extreme
cytokine value had an AR; the patients with the highest levels of
IL-10 and IL-17A experienced grade 1 toxicities (urticaria and
AR, respectively), while the patient with the highest levels of
CXCL9 experienced grade 3 urticaria. It should be pointed out
that any toxicity that occurred between the start of a given course
and before the fourth dose of ch14.18 (day 6 for course 1 or day
90 for course 4), when blood was drawn, were considered for
correlations with cytokine levels.
Among the patients with anaphylaxis, a blood sample was
available from only one patient (during Course 4, Figure 2B;
Table S2 in Supplementary Material) taken the day prior to the
documentation of anaphylaxis. Most of the cytokines levels on
day 90 in this patient were ≤2-fold different from the average
levels of all course 4 AR patients. One exception was IL-17A,
a cytokine known to be associated with food allergy (16). The

Table 6 | Summary of dilution corrected mean of ch14.18 concentration values
(ng/mL).
Study day
6 (peak)
80 (trough)
90 (peak)
111 (trough)
118 (peak)
Completion of
study (trough)

N (patients)

Mean

SD

Median

Min, max

80
78
71
66
63
66

5,965
844
4,650
730
5,907
178

2,463
1,598
2,263
1,468
2,550
188

5.761
341
4,506
362
5,844
126

1,233, 13,380
6, 10,910
34, 9,611
8, 11,630
77, 15,630
1, 890

time points, just prior to starting the third and fourth courses,
with mean concentrations of 844 and 730 ng/ml, respectively.

HACA Response

A total of 533 samples were analyzed for HACA from 103
patients. Eight patients had a confirmed positive HACA response.
All HACA positivity was detected during and after course 3.
No dose modification was done based on HACA development.

Cytokine Profiles and Association
With ARs

After correcting for multiple comparisons, the average levels of
9 of 13 cytokines on course 1, and 11 of 13 on course 4 were
significantly elevated with respect to the pre-treatment values
(Figure 2A; Table S2 in Supplementary Material). IL-5 exhibited
the most dramatic rise during immunotherapy. On the other
hand, IL-4 and IL-18 on course 1 and IL12p70 and IL-8 on both
courses did not change significantly during treatment.
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IL-17A levels in this patient (4.02 ± 0.14) were higher than 29
of 32 (91%) patients who did not have any AR. Furthermore,
of patients who had similar (±20%, N = 4) or higher (>20%,

N = 3) IL-17A levels, four of these patients also experienced
AR, though the patient harboring the highest IL-17A levels
of all patients (20.73 pg/ml) experienced only a grade 1 AR.

Figure 2 | Continued

Frontiers in Immunology | www.frontiersin.org
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Figure 2 | Cytokine and nitrate levels during course 1 and 4 of immunotherapy: (A) changes in serum cytokine and nitrate levels during Immunotherapy.
(B) Relationship between allergic reaction of any grade and serum cytokine levels on immunotherapy. Serum samples were collected before starting immunotherapy
and just before the fourth doses of ch14.18 infusions on courses 1 (days 1 and 6) and 4 (days 80 and 90), and analyzed as described for cytokine and nitrate levels.
Box represents 25–75% distribution, error bars represent SD, solid line is the median, dashed line is the mean. Boxes and values shown include any not-shown
outliers unless otherwise mentioned. (A) Comparisons are by Wilcoxon signed-rank test of paired samples: day −1 versus day 6 and day 80 versus day 90.
A p-value of < 0.0036 is considered statistically significant at level 0.05 and are Bonferroni corrected for the 14 cytokine comparisons at each course, or p < 0.05
for nitrate. Values of outliers excluded from the graph are: d-1: IL-6 (447.4 and 416.7 pg/ml), tumor necrosis factor alpha (268.5 pg/ml), IL-4 (0.78 pg/ml), IL-12p70
(5.48 pg/ml), IL-17A (22.4 pg/ml), IL-8 (31,818 pg/ml and also excluded from the mean, median and statistical determinations); d6: IL-6 (618 pg/ml), IL1-Ra
(11,489.1 pg/ml), CCL22 (39,956.7 pg/ml), IL-15 (19.2 pg/ml); d80: IL-6 (862.0 pg/ml), IL-8 (2,185.5 pg/ml), IL-15 (33.7 pg/ml and 17.1 pg/ml); d90: IL-6
(187.1 pg/ml), IL1-Ra (13,329.9 pg/ml), IFNγ (9,591.9 pg/ml), IL-10 (193.7 pg/ml), IL-4 (0.47 pg/ml), IL-5 (7,500.9 pg/ml), IL-17A (20.7 pg/ml), CXCL9 (24,172.7
and 19,116.1 pg/ml), IL-15 (33.4 pg/ml). (B) Two-sided Mann–Whitney U-test comparison of no AR versus any AR; values are not adjusted for multiple
comparisons. Values of outliers excluded from the graph are: d6, no AR: IL1-Ra (11,489.1 pg/ml), CCL22 (39,956.7 pg/ml), IL-15 (19.2 pg/ml); d6 AR:
IL-6 (618 pg/ml); d90, no AR: IL1-Ra (13,329.9 pg/ml), IFNγ (9,591.9 pg/ml), IL-4 (0.47 pg/ml), IL-5 (7,500.9 pg/ml), IL-15 (33.4 pg/ml); d90 AR: IL-10
(193.7 pg/ml), IL-17A (20.7 pg/ml), CXCL9 (24,172.7 and 19,116.1 pg/ml). Notes: IL-1Ra: interleukin-1 receptor antagonist; many CCL22 values were
out of the range of the multiplex assay and were extrapolated. Thus, the CCL22 data and analyses should be considered qualitative.

Table 7 | Relationship of cytokine and nitrate levels with severe hypotension in ANBL0931 patients.
Course 1, day 6

Course 4, day 90

Cytokine or nitrate

None or ≤ gr2
hypotension

hypotension ≥ gr3

p-Value

None or ≤ gr2 hypotension

hypotension ≥ gr3

p-Value

IL-5 (pg/ml)
Mean ± SE (range)

N = 42
1,043.1 ± 162.7
(27.5–5,114.5)

N=4
148.0 ± 51.9
(12.3–264.9)

p = 0.018

N = 39
1,224.7 ± 211.1
(28.5–5,238.4)

N=7
1,752.0 ± 982.2
(3.6–7,500.9)

p > 0.05

Tumor necrosis
factor alpha (pg/ml)
Mean ± SE (range)

N = 61

N=7

p > 0.05

N = 54

N=8

p > 0.05

11.8 ± 1.5 (2.5–70.6)

8.6 ± 1.4 (4.7–13.6)

19.4 ± 1.3 (5.7–54.4)

15.3 ± 2.1 (7.0–26.0)

IFNγ (pg/ml)
Mean ± SE (range)

N = 61
48.2 ± 8.2
(1.2–317.2)

N=7
26.2 ± 9.9
(2.2–61.0)

p > 0.05

N = 54
354.4 ± 89.7
(0.6–2,511.0)

N=8
1,286.5 ± 1,187.9
(3.1–9,591.9)

p > 0.05

IL-6 (pg/ml)
Mean ± SE (range)

N = 63
31.8 ± 9.8 (1.7–618. 6)

N=7
19.1 ± 4.7 (2.5–35.5)

p > 0.05

N = 55
38.3 ± 5.1 (0.9–187.1)

N=8
26.2 ± 5.3 (1.0–54.7)

p > 0.05

Nitrate (NO3− ) (μM)
Mean ± SE (range)

N = 81
24.2 ± 1.9 (3.5–27.8)

N=8
13.9 ± 3.0 (2.8–27.8)

p = 0.04

N = 67
28.3 ± 2.4 (5.9–102.0)

N = 10
21.0 ± 2.7 (7.6–34.3)

p > 0.05

Cytokines or nitrate during course 1 and course 4 of immunotherapy for association with clinically significant (≥grade 3) hypotension. Mann–Whitney U-test comparisons of cytokines
were considered significant at a p-value of <0.0125 after Bonferroni correction for the four cytokines measured at each course. Nitrate levels were considered significant at p = 0.05.

In contrast, IFNγ in this anaphylaxis patient (32.9 ± 0.3 pg/ml)
was 11–16 fold lower than the average of all d90 patients, AR average and non-AR group average (474.7 ± 169.1, 365.9 ± 139.8,
and 534.6 ± 251.5, respectively, Figure 1B; Table S2 in
Supplementary Material), though 9 other AR patients and 14
non-AR patients had even lower IFNγ levels.

(Table 7). No association of any of the cytokines or nitrate with
hypotension was observed during the IL-2 containing course 4.
Capillary leak incidence varied between 0 and 4% during
different courses (Table 4). Nevertheless, in an exploratory
fashion, we compared the cytokine and serum nitrate profile
among patients experiencing capillary leak of grade ≥ 2 and those
without capillary leak (Table 8). At course 1, IL-6 was the only
cytokine of the four (TNFα, IFNγ, IL-6, IL-5) with higher levels
in the capillary leak population (51.4 ± 27.6, N = 22), than the
population without capillary leak (21.0 ± 2.0, N = 48, p > 0.05)
though not statistically significant. Similarly, no statistically
significant difference was identified for nitrate levels between
the none vs grade ≥ 2 capillary leak subgroups. During course 4,
average IL-5 levels were increased and IFNγ levels were decreased
in the none vs grade ≥ 2 capillary leak subgroups, though again
the groups were not statistically different (Table 8). In contrast to
hypothesized high levels of cytokines, the patient who developed
course 1 grade 3 capillary leak harbored day 6 levels of IL-5 that
were the lowest of all patients, IL-6 the second lowest and TNFα
ninth lowest of the entire analyzed population. On the other
hand, serum IFNγ and nitrate levels appeared similar to the
overall patient cohort (26th lowest of 68 patient samples for IFNγ

Cytokine and Nitrate Profiles and
Association With Vascular Disorders

As IL-5 levels were dramatically elevated on both courses inves
tigated, we explored a possible relationship of this cytokine
and the other analytes implicated with vascular disorders for
associations with clinically significant (≥grade 3) hypotension
(Table 7), or any grade capillary leak (Table 8). During course 1,
hypotension was associated with lower IL-5 levels (p = 0.018),
though, none of the associations met the required level for
statistical significance when adjusted for the four analytes compared (p < 0.0125). Nitric oxide, as measured by the more stable
precursor nitrate, showed a small but significant decrease in
patients with ≥ grade 3 hypotension during course 1, contrary to
the expected association of higher nitrate levels with hypotension
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Table 8 | Relationship of cytokine and nitrate levels with capillary leak in ANBL0931 patients.
Course 1, day 6

Course 4, day 90

No capillary leaka

Capillary leak ≥ gr2b

p-valuec

No capillary leaka

Capillary leak ≥ gr2d

p-valuec

IL-5 (pg/ml)
Mean ± SE (range)

N = 30
903.3 ± 133.4
(27.5–2,787.7)

N = 16
1,081.4 ± 369.4
(12.3–5,114.5)

p > 0.05

N = 25
757.9 ± 105.8
(3.6–2,175.8)

N = 21
1,956.1 ± 450.2
(28.5–7,500.9)

p > 0.05

IL-6 (pg/ml)
Mean ± SE (range)

N = 48
21.0 ± 2.0 (1.7–72.6)

N = 22
51.4 ± 27.6 (2.5–618.6)

p > 0.05

N = 39
34.8 ± 5.0 (1.0–124.2)

N = 24
40.0 ± 8.7 (0.9–187.1)

p > 0.05

N = 46

N = 22

p > 0.05

N = 38

N = 24

p > 0.05

Cytokine or nitrate

Tumor necrosis factor
alpha (TNFα) (pg/ml)
Mean ± SE (range)

9.6 ± 0.7 (2.5–23.7)

15.4 ± 0.3 (3.0–70.6)

17.6 ± 1.0 (6.0–35.7)

20.8 ± 2.6 (5.7–54.4)

IFNγ (pg/ml)
Mean ± SE (range)

N = 46
47.7 ± 10.0 (1.2–317.2)

N = 22
42.2 ± 10.2 (1.4–194.8)

p > 0.05

N = 60
628.6 ± 266.5 (3.1–9,591.9)

N = 24
231.0 ± 103.8 (0.6–2,459.6)

p > 0.05

Nitrate (NO3− ) (μM)
Mean ± SE (range)

N = 65
23.2 ± 2 (2.8–106.41)

N = 24
23.6 ± 3.3 (3.8–79.9)

p > 0.05

N = 48
25.8 ± 2.5 (5.9–102.0)

N = 29
29.8 ± 3.8 (7.2–98.7)

p > 0.05

There were no grade 1 capillary leak diagnoses.
One patient was diagnosed with grade 3 while the rest were grade 2. Compared to the group as a whole (see Table S2 in Supplementary Material), this patients levels of IL-5 were
the lowest, IL-6 the second lowest and TNFα ninth lowest. IFNγ and nitrate appeared similar to the group as a whole (#26 for IFNγ and #69 for nitrate).
c
Test of association of cytokine or nitrate levels with capillary leak (none versus grade ≥ 2) using a two-sided Mann–Whitney U-test at a p-value of < 0.05 without correction for
multiple comparisons.
d
Two patients were diagnosed with grade 3 capillary leak at this time point while the rest were grade 2.
a

b

IL-6 during course 1 or course 4 (Figures 4C–D and data not
shown).

and 69th lowest of 89 patient samples for nitrate). For the two
patients with grade 3 capillary leak during course 4, we observed
a cytokine expression pattern similar to that observed in the
patient who developed capillary leak during course 1, with very
low IL-5 (second and fifth lowest), IL-6 (fourth and eleventh
lowest), and TNFα (sixth and thirteenth lowest). However, in
contrast to day 6, IFNγ levels in these two patients were the lowest
and second lowest of all patients measured. Among the 56 unique
patients who reported Grade 2 or 3 capillary leak syndrome, 32
patients reported in more than one course. Fourteen patients
reported in two, 4 reported in three, 9 reported in four, and 5
reported in five courses.

DISCUSSION
The immunotherapy regimen of ch14.18, GM-CSF and IL-2,
has been shown to be efficacious in high-risk NB patients with
minimal residual disease and is now the standard FDA-approved
therapy (1). This confirmatory study was conducted to collect
the additional detailed safety data required to support a BLA
to FDA for ch14.18 (dinutuximab), which was successful. The
nominal dose of dinutuximab (17.5 mg/m2/day) differs from
the dose of NCI ch14.18 (25 mg/m2) because of a difference in
the extinction coefficient used to determine the protein concentration during the manufacturing process, but despite the change
in nominal dosing, the amount of antibody delivered per dose
is equivalent for the two products. Marachelian et al. reported
a dinutuximab dose of 17.5 mg/m2 and NCI ch14.18 dose of
25 mg/m2 producing comparable exposures, with no notable
safety or tolerability differences in a randomized, two-sequence
crossover study (17). Overall, this study confirmed the toxicity
data and efficacy previously obtained in the ANBL0032 trial (1).
Moreover, we demonstrate toxicities that are severe but manageable. No new or unexpected toxicities were encountered.
The side-effect profile of this immunotherapy differs greatly
from traditional cytotoxic therapy. While the majority of
ch14.18 related toxicities are acute, temporarily related to infusion
of antibody, and manageable with supportive care (e.g., fever,
neuropathic pain); some can be life threatening and impact
the ability to administer this therapy (e.g., anaphylaxis and/or
bronchospasm). This study confirmed the need for close patient
monitoring with hospitalization for administration of the
described administration schedule to ensure timely response to
required supportive care. Infrequently, ocular toxicities of diplopia, dilated pupils or both occurred, lasting for longer duration.

Disease Outcome

The 3-year EFS and OS rates (n = 105) were 67.6 ± 4.8 and
79.1 ± 4.2%, respectively (Figure 3A). For the subset of
patients > 18 months of age with INSS Stage 4 disease (n = 56),
the 3-year EFS and OS rates were 58.9 ± 6.8 and 74.6 ± 6.0%,
respectively (Figure 3B). There was no difference in EFS between
patients who received ≥ 90% (n = 79; 3-year EFS: 70.3 ± 5.4%)
vs. <90% (n = 25; 3-year EFS: 57.6 ± 10.4%) of the cumulative
ch14.18 dose intended (log-rank p-value = 0.1486). There was no
significant difference in the progressive disease rate between the
lowest and highest quartiles when analyzed based on the cumu
lative ch14.18 received per patient (chi-square p-value = 0.7306).

Cytokines and Outcome

Levels of IL-6 and other cytokines prior to initial chemotherapy
have been associated with outcome in numerous cancers including NB (10, 11). However, among the 15 analytes measured at
four treatment time points in two courses of maintenance phase
immunotherapy, only CXCL9 at day −1 showed an association
with EFS (p = 0.05, not Bonferroni corrected, Figures 4A–B).
No association with OS was observed nor was there any outcome
association with changes in levels of any of the analytes including
Frontiers in Immunology | www.frontiersin.org
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We chose to prolong the initial infusion time of ch14.18 to
≥10 h for all patients in this study compared to the 5.75 h infusion
on ANBL0032. There is evidence that prolongation of the infusion time is associated with less toxicity. Lode et al. has reported
decreased toxicity with continuous IV infusion of ch14.18/CHO
(ch14.18 produced in Chinese hamster ovary cells) over 10 days
in combination with IL-2 when compared to the same dose of
ch14.18/CHO (100 mg/m2 as total dose) administered IV daily
over 8 h for 5 days (18). This prolonged continuous infusion
approach allowed a comparable dose of ch14.18/CHO to that
used here, to be administered in the outpatient setting. Analysis
of the safety and toxicity associated with short vs. prolonged
(≥10 h) infusion of ch14.18 on ANBL0032 is planned and when
combined with the results of this and other studies will help

0.6
0.4

Event−Free Survival
Overall Survival

0.0

0.2

Probability of Survival

0.8

1.0

A

determine the optimal infusion duration that may mitigate toxi
cities and potentially the cost of therapy administration.
Navid et al. reported the results from a phase I trial using
a novel anti-GD2 agent, hu14.18K322A, designed to decrease
neuropathic toxicity through decreased complement binding
(4). Kushner et al. reported multifold dose escalation of heat
modified 3F8 resulting in less toxicity and allowing administration in the outpatient setting (19). However, the differences
in administration schedule, cytokine use and toxicity grading
impair our ability to directly compare toxicity rates across these
clinical trials (20).
The pharmacokinetics of ch14.18 in children with NB was
previously characterized by intra- and inter-patient variability
(21). Desai et al. studied detailed pharmacokinetics of ch14.18
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Figure 3 | Continued
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Figure 3 | (A) Event-free and overall survival (OS) from time of enrollment for patients on COG ANBL0931 (n = 105). (B) Event-free and OS from time of enrollment
for patients > 18 months of age with INSS Stage 4 disease on COG ANBL0931 (n = 56).

in 14 pediatric subjects who received identical immunother
apy as delivered on ANBL0931 and demonstrated less variable
ch14.18 disposition than previously reported (13). In compa
rison, pharmacokinetics profiles obtained through a very limi
ted sampling on ANBL0931 demonstrated lower mean peak
ch14.18 concentrations (5.5 vs 11 mcg/ml) but higher mean
trough concentrations (0.78 vs 0.2 mcg/ml) than reported by
Desai. This difference could be a function of limited sampling
in both studies. Similar to prior experience with ch14.18 when
administered following ASCT in patients with NB (1), the
development of HACA was uncommon. No dose modification
was done based on HACA results in our patients.
Cytokines can orchestrate inflammation and immunity
and can be key players in toxicity reactions such as AR in

Frontiers in Immunology | www.frontiersin.org

general, and anaphylaxis in particular. The course-associated
average increases in cytokine levels reflected individual increa
ses in the vast majority of patients despite a large range of
variation. These increases may be due to the administration of
cytokines GM-CSF and IL-2 during therapy, due to ch14.18, or
both. However, cytokine levels of the patients experiencing AR
appeared similar to those of patients who did not experience
AR. IL-5 exhibited the largest course-associated fold-increase in
patients vs. normal controls, as much as 20,000-fold higher and
is reported to promote IgE and eosinophilic responses (22), while
IL-5 did have an association with hypotension, it did not have an
association with AR in patients on immunotherapy.
Cytokines can also promote tumor cell growth, migration, and
metastasis or create an immunosuppressive microenvironment
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Figure 4 | CXCL9 and IL-6 versus survival in immunotherapy treated patients. CXCL9 (A,B) and IL-6 (C,D) were measured in the serum of ANBL0931 patient
samples obtained at pretreatment to course 1. Patient values were sorted as to above or below median levels of all patients and a Kaplan Meier survival analysis
for event-free survival (A,C) and OS (B,D) assessed and significance assessed by Log Rank test.

(23). CXCL9 is a T- and NK-cell chemoattractant that displays
antitumor and pro-tumor activities. Consistent with this
observation, high levels of serum CL1 chemokine cluster, which
includes CXCL9, was correlated with an shorter OS in chronic
lymphocytic leukemia (11), suggesting that high levels of CXCL9
and related chemokines might predict a poor prognosis in NB
as well.
IL-6 has also been reported to be part of a multi-protein
biomarkers signature in a retrospective study to be associated
with relapse in high risk NB (24). In this study, there was no
association of IL-6 with event or outcome before and during
maintenance phase immunotherapy plus cytokines. However,
we must caution about possible variable time between blood and
plasma isolation in the reported retrospective study (24), knowing that handling of sample can greatly affect measured levels
of cytokines (25, 26), and our own data demonstrating highly
variable and often unreliable cytokine values when measured in
plasma (unpublished observations). Thus, while IL-6 levels may
be able to predict outcome for some types of chemotherapy when
measured at diagnosis, or retrospectively predict relapse, its level
at the start of maintenance phase with ch14.18 immunotherapy
is not prognostic of outcome.
The induction of nitric oxide as a consequence of IL-2 administration is thought to be responsible for immunotherapy-associated capillary leak syndrome and hypotension (7, 8). However,
nitric oxide levels, as determined through the measurement of

Frontiers in Immunology | www.frontiersin.org

the more stable metabolite nitrate, were slightly but significantly
decreased in a paired samples analysis during both GM-CSF
and IL-2 courses of therapy, and were paradoxically associated
with severe hypotension in the non-IL-2 containing course 1.
In the single patient who developed course 1 severe capillary
leak, nitrate levels were similar to those of the group as a whole.
These data suggest that the cause of immunotherapy-associated
vascular disorders is not due to nitrate release. However, given
the known role of nitric oxide in vascular relaxation, it is hard to
understand the decrease in nitrate levels during immunotherapy,
or why lower levels might be associated with hypotension, though
it may be as simple as timing of the blood sample draw versus the
observation of toxicity.
Several cytokines showed associations with the occurrence of
hypotension and capillary leak. However, as with nitrate, lower
levels of some cytokines were associated with vascular disorders.
In particular, the capillary leak patients had some of the lowest
cytokine levels of all samples analyzed. Considering the dramatic
increase in cytokines we have observed during the course of
therapy and the reported relationships of elevated TNFα and IL-6
with vascular permeability (27), this is a paradoxical observation.
One might speculate that the increase in cytokines we observed
during therapy may be a protective response that helps maintain
vascular integrity. In patients with low cytokine levels, this
protective response may be compromised and be reflected in the
observed vascular disorders. Thus, when compared to patients
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whose cytokine levels remain elevated, these patients would
appear to have very low cytokine levels. Finally, the possibility
that immunotherapy is suppressing cytokine release in some
patients cannot be excluded.
In summary, this study confirmed the significant, but manageable treatment-related toxicities of the immunotherapy including
pain, ARs, hypotension and capillary leak syndrome observed
in the ANBL0032 study, patterned the dramatic increase in
cytokine release during immunotherapy, validated the excellent
EFS and OS rates of this immunotherapy combination treatment
(1) and implicated the chemokine CXCL9 as mildly prognostic
at pretreatment.
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